18 Share Tips | 18th December 2023 | The Bull
"BUY – Botanix Pharmaceuticals (BOT)This clinical dermatology company is seeking US Food and Drug Administration (FDA) approval for its leading product Sofpironium Bromide gel (Sofdra) for treating axillary hyperhidrosis (excessive sweating). The initial application was denied by the FDA due to unclear instructions about using the product. The company is on target to submit its final component to the FDA in the first quarter of fiscal year 2024. BOT is targeting FDA approval by mid-2024. The company has advised the planned content of materials proposed to be re-submitted are acceptable to the FDA. No additional materials have been requested by the FDA. The company has recently raised $13.5 million in preparation for a product launch and marketing. This stock is more suited to investors with an appetite for risk."
18 Share Tips | 18th December 2023 | The Bull"BUY – Botanix...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $346.5M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $556.8K | 2.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 188599 | 5 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
21.8¢ |
Change
0.000 ( 1.09 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.0¢ | 21.5¢ | 1397313 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| BOT (ASX) Chart |